产品名称 | NebuSelect™ Recombinant Human IL-19, hFc-tag |
---|---|
目录号 | NBL-242451 |
别名 | IL-19; Interleukin-19; IL-19; ZMDA1; IL-10C; MDA1; NG.1 |
外观 | see COA |
分子量 | Leu25-Ala177 |
CAS | N/A |
溶解度 | Water Soluble |
存储条件 | Short term 4℃; Long term -20℃. |
保存时间 | 2 years |
备注1 | Q9UHD0-1 |
备注2 |
目录号 | 规格 | 价格 | 库存状态 | |
NBL-242451-100ug | 100ug | Inquire | Inquire | |
NBL-242451-1mg | 1mg | Inquire | Inquire | |
NBL-242451-Customized Size | N/A | Inquire | Inquire |
Product Name:
NebuSelect™ Recombinant Human IL-19, hFc-tag
Catalog#:
NBL-242451
Description:
NebuSelect™ Recombinant Human IL-19, hFc-tag(Cat#NBL-242451) is expressed in HEK293 with hFc tag at the C-Terminus.It contains Leu25-Ala177.
Species:
Human
Expression System:
HEK293
Molecular Weight:
The protein has a predicted MW of 44.6 kDa. Due to glycosylation, the protein migrates to 55-60 kDa based on Bis-Tris PAGE result.
Target Name:
IL-19; Interleukin-19; IL-19; ZMDA1; IL-10C; MDA1; NG.1
Target Information:
Interleukin-19 (IL-19) has been shown to be involved in coronary artery diseases and atherosclerosis, while its expression in myocardial infarction is poorly understood. In this study, the dynamic increase in circulating IL-19 in acute ST-segment elevation myocardial infarction (STEMI) patients was detected.IL-19 is correlated with the severity of acute myocardial infarction, which may be a new idea for the clinical treatment of myocardial infarction.
Amino Acid Sequence:
Leu25-Ala177
Purity:
>95%
Formulation:
see COA
Endotoxin:
<1EU/ug(LAL Method)
Storage:
4°C for short term.
-20°C for long term.
To get more information, please contact us freely.